PTCT - PTCセラピュ―ティクス (PTC Therapeutics Inc.)

PTCTのニュース

   PTC Therapeutics GAAP EPS of -$1.78 misses by $0.27, revenue of $149M beats by $2.1M  2022/05/03 20:05:23 Seeking Alpha
   PTC Therapeutics Q1 2022 Earnings Preview  2022/05/02 21:45:00 Seeking Alpha
PTC Therapeutics (PTCT) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, after market close.The consensus EPS Estimate is -$1.66 and the consensus Revenue Estimate…
   PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results  2022/04/19 12:00:00 PR Newswire
SOUTH PLAINFIELD, N.J., April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company''s business and outlook on Tuesday, May…
   PTC Therapeutics expects EMA committee opinion on AADC deficiency gene therapy in May  2022/04/14 13:27:17 Seeking Alpha
Biopharmaceutical company PTC Therapeutics (PTCT) on Thursday said it has completed procedural meetings for its gene therapy treatment for ((AADC)) deficiency with the European Union…
   PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases  2022/04/11 11:13:37 Seeking Alpha
   PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $40.85  2021/12/23 16:08:44 Transcript Daily
PTC Therapeutics, Inc. (NASDAQ:PTCT) gapped down before the market opened on Thursday . The stock had previously closed at $40.85, but opened at $39.58. PTC Therapeutics shares last traded at $41.26, with a volume of 80 shares. PTCT has been the subject of several research analyst reports. Credit Suisse Group reduced their target price on []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to Post Quarterly Sales of $134.21 Million  2021/12/21 21:34:44 Transcript Daily
Equities research analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to announce sales of $134.21 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for PTC Therapeutics earnings. The lowest sales estimate is $96.34 million and the highest is $162.70 million. PTC Therapeutics posted sales of $118.86 million in the same quarter []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Fisher Asset Management LLC  2021/12/16 10:26:42 Transcript Daily
Fisher Asset Management LLC lifted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 9.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,156 shares of the biopharmaceutical companys stock after purchasing an additional 15,671 shares during []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Invesco Ltd.  2021/12/09 09:46:42 Dakota Financial News
Invesco Ltd. grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 39,623 shares of the biopharmaceutical companys stock after buying an additional 11,041 shares during the quarter. Invesco Ltd.s holdings in PTC Therapeutics were worth $1,675,000 at the end of the most recent []
   Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight  2021/12/08 01:00:00 Benzinga
Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.
   Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH  2021/06/11 05:00:00 Business Insider Markets
SOUTH PLAINFIELD, N.J., June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy (SMA) treated with
   Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH  2021/06/11 00:00:00 BioSpace
PTC Therapeutics, Inc. announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently.
   Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics'' Board of Directors  2021/06/09 12:00:00 PR Newswire
SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company''s Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a
   William Blair Thinks PTC Therapeutics Stock is Going to Recover  2021/06/03 08:06:48 Smarter Analyst
In a report released today, Raju Prasad from William Blair maintained a Buy rating on PTC Therapeutics (PTCT). The companys shares closed last The post William Blair Thinks PTC Therapeutics Stock is Going to Recover appeared first on Smarter Analyst .
   PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia  2021/05/26 00:00:00 BioSpace
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that can lead to cognitive disabilities and seizures

calendar